Professional Documents
Culture Documents
History:
Cadila Healthcare Ltd is a well known research-oriented, technology-driven
pharmaceutical company focused on the research areas of biotechnology, formulations
and Active Pharmaceutical Ingredients. They are an Indian based pharmaceutical
company having their presence around the world. They are having their manufacturing
facilities at Ahmedabad, Ankleshwar and Vadodara in Gujarat, Ponda in Goa, Raigad in
Maharashtra and Solan in Himachal Pradesh.
Cadila Healthcare Ltd, the flagship of Zydus Cadila Group was incorporated in May 1995
and they became a public limited company in July 1996. The company's operation
includes pharmaceuticals, which includes human formulations, veterinary formulations
and bulkdurgs, diagnostics, herbal products, skin care products and OTC products.
In the year 1996, the company made a strategic alliance with Gulin Pharma of China and
launched Falcigo in India, which is an anti-malarial segment. In May 2000, the company
acquired formulation business of Recon Ltd, which strengthens the company in the
southern market. In the year 2001, they acquired German Remedies which was the largest
M&A in the Indian Pharmaceutical sector and in the same year, they entered into a joint
venture with US based Onconova for collaborative research in the field of
Oncogenomics.
In April 2002, the company acquired Banyan Chemicals, a Vadodara based company
with the US FDA approved plant. In the year 2003, German Remedies, Recon
Healthcare, Zoom Properties and Zydus Pathline merged with the company. Also, they
acquired Alpharma France, which spearheaded the group operations in France. In the
same year, the company emerged as a 'Partner of Choice' for Schering AG to manufacture
and market the products in India.
In November 2004, the company entered into a strategic alliance with Zambon Group in
Italy to open up new avenues in contract manufacturing. In the same year, the company
entered into a long term strategic pact with Boehringer Ingelheim India Ltd, a wholly
owned subsidiary of Boerhringer Ingelheim (BI) to manufacture and market BI's products
in India.
In the year 2005, the company entered into a strategic alliance with Mallinckrodt
Pharmaceuticals Generics, a business unit of Tyco Healthcare to market the product
manufactured by the company under a joint label. In the same year, the company signed a
50:50 joint venture with Mayne Pharma of Australia to manufacture generic injectable,
cytotoxic (anti-cancer) medicines as well as active pharmacetical ingredients (API) for
global markets.
During the year 2005-06, the company signed a 50:50 joint venture with one of India's
top biotech companies Bharat Serums and Vaccines Ltd (BSV) and formed Zydus BSV
Pharma Pvt Ltd to develop, manufacture and market non-infringing and proprietary
Novel Drug Delivery System (NDDS) of an approved anti-cancer product for global
markets.
During the year 2006-07, the company entered into share purchase agreement to acquire
97.95% stake in Liva Healthcare Ltd, which is carrying on business of manufacturing and
marketing of Formulations. They established a green field facility for Solid Oral Dosage
Forms in Sikkim mainly for domestic market. They also installed Lyophilisation facility
at Moraiya plant with annual capacity of 7.5 million dosages to cater to both Indian and
International markets.
During the year 2007-08, the company restructured their formulation division namely
Alidac and launched two new sub division namely Corza and Fortiza. Also, they forayed
into the neutraceutical industry and launched a new division, Zydus Nutriva. The
upgradation of the injectibles facility at Moraiya was completed and also, they expanded
their manufacturing facility at Ankleshwar.
Zydus Healthcare Brasil Ltd, Brazil, a wholly owned subsidiary of the company acquired
100% shareholding of Quimica e Farmaceutica Nikkho Do Brasil Ltda, a Brazilian
Pharmaceutical company to expand their branded business in Brazil. Also, Zydus
Pharmaceuticals Inc, Japan, a wholly owned subsidiary of the company acquired 100%
shareholding in Nippon Universal Pharmaceuticals Co Ltd, Japanese Company, which is
carrying out business of manufacturing and marketing of pharmaceutical products in
Japan.
In February 2008, the company and Karo Bio of Sweden made a three year strategic
collaboration in the area of drug discovery and development. The company is in the
process of setting up a fine chemical facility at Dabhasa at a cost of about Rs 200 million,
which will commence their production in the financial year 2008-09.
In May 2008, the company entered into Spain with the acquisition of 100% stake in
Laboratories Combix. In June 2008, the company through their wholly owned subsidiary,
Zydus Healthcare SA Pty Ltd is acquiring majority state of 70% in Simayla
Pharmaceuticals of South Africa.
The company decided to demerge the Consumer Products Division of the company and
transferred to Carnation Nutra Analogue Foods Ltd, which is a subsidiary of Cadila
Healthcare and the merger of Zydus Hospital and Medical Research Pvt Ltd with the
company.
In August 2008, the company has entered into an agreement with WHO to explore a
possible collaboration in the development of a cocktail for the treatment of rabies,
through the use of monoclonal antibodies.
In its mission to create healthier communities globally, Zydus Cadila delivers wide
ranging healthcare solutions and value to its customers. With over 11,000 employees
worldwide, a world-class research and development centre dedicated to discovery
research and eight state-of-the-art manufacturing plants, the group is dedicated to
improving people’s lives.
About US
A mission to create healthier communities
Zydus Cadila is dedicated to life…
In all its dimensions. Our world is shaped by a passion for innovation, commitment to partners and concern
for people in an effort to create healthier communities, globally.
A vision that unleashes value
To be a leading global healthcare provider with a robust product pipeline and sales of over $1 bn by 2010;
we shall achieve sales of over $3 bn by 2015 and be a research-based pharmaceutical company by 2020.
The portfolio of over 200 products are marketed by a specialised field force of 3,000. With one of the
strongest distribution channels in the industry, the group reaches out to 1,00,000 chemists and serves
2,00,000 doctors including physicians, specialists and super specialists.
Apart from a strong presence in the prescription market, the group also caters to the growing
health and wellness segment through its subsidiary Zydus Wellness Ltd.
Zydus Wellness aims to promote ‘healthy living’ by anticipating the emerging and day-to-day
needs in dietetic / health foods. Health and wellness have been identified as the emerging areas
in consumer healthcare. The Company is focussed on empowering individuals who wish to adopt
healthy eating habits and lifestyles.
The Company is a pioneer, offering healthier dietary options to the consumers. The product range
comprises Sugar Free Gold– India’s No.1 sweetener with a market share of over 70%, Sugar Free
Natura– a zero calorie sucralose based sugar substitute, Sugar Free D’lite– a low calorie healthy
drink and Nutralite– a premium cholesterol-free table spread. Nutralite has emerged as the
second largest brand in the category of butter and butter substitutes.
The Company also caters to the skincare segment with its Everyuth and Dermacare brands,
which occupy a unique distinction of being a ‘skincare brand from a healthcare company’.
Enriched with the power of natural ingredients, EverYuth has a strong presence in advanced
skincare segments like soap-free, face washes, face masks, scrubs etc.
Zydus Cadila has strong global opetations to market both formulations and APIs. With operations
in U.S.A., Europe, Latin America, Japan and over 40 emerging markets across the world, Zydus
Cadila is a global healthcare provider. The group also manufactures and markets a wide range of
intermediates and APIs.
Manufacturing:
A wide range of capabilities have helped the group create a robust manufacturing infrastructure. Spread
over five states of India, the group has eight state-of-the-art manufacturing facilities, creating a strong global
manufacturing hub for the group.
Formulations
Key Factors:
• Zydus Cadila is a global healthcare provider and one of the top five pharma companies in India.
The company was founded by Late Mr. Ramanbhai B. Patel in 1952 and went on to become the second
• In 1995, the group restructured its operations and now operates as Cadila Healthcare Ltd., under
the aegis of the Zydus group. The company spearheaded by Mr. Pankaj R. Patel, Chairman and Managing
• The group has been listed as one of the ‘Best Under a Billion’ company from amongst 200
• Proven expertise in manufacturing and marketing different dosage forms such as solid dosage
forms, injectables, metered dose inhalers, dry powder inhalers, transdermal patches, suppositories and
oncology formulations.
• Wide therapy coverage through three multi-therapy divisions and eleven speciality divisions. The
divisions are spearheaded by some of the stalwarts in the field of pharma marketing.
• A dedicated field force of 3300 reaches out to super specialists, specialists, surgeons, physicians
• The group has a strong presence in the cardiovascular, gastrointestinal, women’s healthcare
segments, respiratory, pain management, CNS, anti-infectives, oncology, neurosciences, dermatology and
nephrology segments.
• Leading the way through new product introductions, the group was the first to launch Nucoxia
(Sildenafil Citrate), Providac Techsules, Betaferon, Fludara, Slimona (Rimonabant) and Novolizer in India.
• The group has several brands that feature amongst the top 300 pharmaceutical brands in India.
• The group has a globally compliant manufacturing infrastructure comprising eight state-of-the-art
facilities which support product launches not just in India but also in the regulated markets of U.S., Europe
• Three of the group’s facilities including the formulation manufacturing plant at Moraiya, and API
plants at Ankleshwar and Dabhasa near Vadodara are approved by the USFDA.
• Over 350 scientists are working on new molecular entity research at the Zydus Research Centre.
• Zydus Cadila is a partner of choice for several global pharma majors such as Boehringer
Ingelheim, Bayer Schering Pharma, Madaus AG, Nycomed, Hospira, Bio Sidus of Argentina, Mallinckrodt
• One of the most reputed pharma companies globally, Zydus Cadila aims to be a leading global
healthcare provider with a robust product pipeline and sales of over $1 billion by 2010. It plans to achieve
Core value:
In the community:
In keeping with its mission to create healthier communities globally, Zydus Cadila is actively
involved in developing the community of which it forms a part.
Through the Ramanbhai Foundation, it has undertaken initiatives in the field of pharmaceutical
research, education and healthcare. Under the aegis of the Foundation, the group organises an
International Symposium on the latest trends in Pharmaceutical Sciences, once every two years.
Three International symposia have been held so far with more than 40 research scientists,
academicians and research professionals from across the world sharing their insights on the
latest developments in pharmaceutical research.
‘The Zydus School for Excellence’ – a centre for learning where young minds are free to grow in
relationship to his or her potential has also been set up under the aegis of the Foundation. The
‘Shri Ramanbhai Patel Memorial Scholarship Programme’ jointly funded by a grant from the
Ramanbhai Foundation and Zydus School for Excellence funds the education of students from
disadvantaged backgrounds.
Shri Ramanbhai B. Patel - AMA Centre for Excellence in Education, provides a platform for
parents, teachers and students to highlight the critical educational issues of the day. The centre
conducts open house discussions, memorial lectures on excellence in education, progressive
learning programmes for academicians and knowledge sharing forums. The centre also honours
teachers for their contributions to a child’s world of learning.
Dedicated to the memory of the group’s founder, the IPA – Shri Ramanbhai B. Patel Foundation
(IRF) has been jointly set up with the Indian Pharmaceutical Association. IRF recognises and
honours ‘commitment and excellence’ in the field of pharmacy.
As a part of its outreach programmes, the group organises rural healthcare camps annually with
its team of medical advisors and employees, volunteering their services. So far, the group has
organised general healthcare camps, diagnostic, dental-care, eye-care and paediatric camps.
The group has also initiated 'Project Unnati' for adolescent girls at Moraiya which focusses on
health and overall development.
Through the Ramanbhai Foundation, the group also extends its support during times of natural
calamities.
In recognition of its CSR initiatives, the group bagged the ‘Social and Corporate Governance
Awards 2008’ in the ‘Best Social Responsibility Practice’ category presented by the BSE,
NASSCOM Foundation and Times Foundation
Research Focus:
At Zydus Research Centre (ZRC), our focus is on finding innovative therapies for diseases affecting
mankind through continuous research and development. The major areas of research includes:
ZRC has constituted a Scientific Advisory Board comprising of world renowned scientists and clinicians to
advice the group in its research endeavors.
In addition to the Scientific Advisory Board, ZRC also has well-experienced advisors to help the
research team in making appropriate decisions on various targets and research areas of focus to the
company.
The Otto Naegeli Award 2002 and the European Lipid Science Award 2002 have honored the work of Dr.
Walter Wahli who has discovered novel nuclear hormone receptors, has identified specific ligands for these
receptors, and has demonstrated the central physiological significance of these regulatory proteins in
metabolism, inflammation, and wound healing. Dr. Wahli has published many publications in well respected
and peer viewed journals and earned a respectable position in exploring mechanism of different diseases
related to nuclear receptors.
About ZRC:
Zydus Research Centre (ZRC) is the dedicated research and development arm of Zydus
Cadila, established in the year 2000. This state-of-the-art research centre, spread over an
area of 3,60,000 sq.ft., is located at Ahmedabad, in the western part of India. A team of
over 300 research scientists are actively engaged in research in various disciplines of
Medicinal Chemistry, Biotechnology, Cell Biology, Bioinformatics, Genomics,
Molecular Biology, Pharmacology, Toxicology, Microbiology, Analytical Research,
Clinical Research, Novel Process Research and Novel Drug Delivery Research.
Research Areas:
Zydus Research Centre (ZRC) is the dedicated research and development arm of Zydus Cadila, established
in the year 2000.
NME research
• Metabolic Disorders
• Diabetes
• Obesity
• Dyslipidemia
• Inflammation and Pain
• Rheumatoid arthritis
• Pain
• Bacterial Infections
Biotechnology Research
R&D Organisation:
The R & D Organisation has capabilities to conduct Drug Discovery and Development from
concept to IND enabling pre-clinical and clinical development.
Scientific Activities:
The Ramanbhai Foundation International Symposium is a biannual series of
symposia devoted to the discussion of new trends in the pharmaceutical industry with
a view to promoting scientific excellence in drug discovery and development.
To learn more about this biannual event and participate, please visit www.rbfsymposium.net
Discovery Pipeline:
Several NME's are under biological testing for treatment of arthritis, obesity and cardiovascular diseases.
Department of Biotechnology
Patents
ZRC has filed over 108 patents in various therapeutic areas of NME research, Process Research, Novel
Process Research, Novel Drug Delivery and Biologicals, since its inception. Several of them have already
been granted US patents
Publications:
ZRC encourages scientists to publish their research findings in leading national and international journals.
Some of the publications from
ZRC are listed below :
• Diaryl Dihydro pyrazole 3-carboxamides with significant in vivo antiobesity activity related to CB1
antagonisum: synthesis,Biological evaluation,and molecular modeling in the homology model.
Journal of Medicinal Chemistry, 2007, 50, 5951-5966
• Synthesis and in vitro antibacterial activities of novel oxazolidinones Eur. J. Med. Chem. 2007, In Press,
Corrected Proof, Available online 27 May 2007 (doi:10.1016/j.ejmech.2007.05.003).
• Direct injection, column switching–liquid chromatographic technique for the estimation of rabeprazole in
bioequivalence study
Journal of Chromatography B, 2004, 813, 247–254.
Collaborations:
Zydus Cadila is constantly seeking newer opportunities in:
Business Development
Zydus Research Centre
Sarkhej-Bavla N.H. No. 8A
Moraiya, Ahmedabad - 382210
Gujarat, India
Ph: +91-2717-250801
Fax: +91-2717-250606
Email: zrc@zyduscadila.com
Investor:
It is our endeavour to provide the latest information for the benefit of the investing community. This section
also provides for downloading of various forms such as those for requesting change in address, transfer of
shares and for issuance of share certificates.
We welcome your suggestions and comments about the various features and facilities provided in this
section. We would also like to know from you other features or facilities that you would like us to provide in
this section.
Shareholding pattern for the quarter ended on 30th June, 2010
(A) Shareholding of
Promoter and
Promoter Group
(1) Indian
(2) Foreign
(2) Non-Institutions
(b) Individuals -
2. Individual
shareholde
rs holding
nominal
share
capital in
excess of
Rs.1 lakh.
(c) Any Other 606 2801352 2781780 1.37 1.37 N.A. N.A.
(specify) NRI/OCB
Sr. Name of the Total shares held Shares pledged or otherwise encumbered
No. Shareholder
Number of Shares as a Number As a percent- As a % of
Shares percentage of tage grand total (A)+
total number of (B)+(C) of sub-
shares {i.e., clause (I)(a)
Grand Total
(A)+(B)+(C)
indicated in
Statement at
(III) Para (I)(a) (V)
(I)
above} (VI)= (V)/ (VII)
(II)
(IV) (III)*100
TOTAL Nil - -
Sr. Name of the DR Holder Type of outstanding DR Number of shares Shares underlying
No. (ADRs, GDRs, SDRs, underlying outstanding DRs as a
etc.) outstanding DRs percentage of total number
of shares {i.e., Grand Total
(A)+(B)+(C) indicated in
Statement at Para (I)(a)
above}
TOTAL Nil -